{
  "symbol": "KNSA",
  "company_name": "Kiniksa Pharmaceuticals International Plc",
  "ir_website": "https://investors.kiniksa.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference",
          "url": "https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-pharmaceuticals-present-7th-annual-evercore-isi",
          "content": "[ Skip to main navigation ](#main-menu)\n\nClose\n\n## Here for you, _every second_\n\nArea of Interest*Medical InformationBusiness DevelopmentHuman ResourcesInvestor & MediaPatient AdvocacyData Privacy\n\nSubmit\n\n*Required\n\n## Locations\n\n  * **United Kingdom** Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ\n  * **USA Headquarters** Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100\n  * **Switzerland** Kiniksa Pharmaceuticals, GmbH Grafenaustrasse 5 6302 Zug, Switzerland\n  * **USA California** Kiniksa Pharmaceuticals Corp. 4660 La Jolla Village Drive Suite 1025 San Diego, CA 92122\n\n\n\n[ ![Home](/sites/g/files/knoqqb90321/themes/site/nir_pid2524/dist/themes/custom/kiniksa/logo.png) ](https://www.kiniksa.com/)\n\nMenu\n\n#  Press Release Details \n\n## \n\nKiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference\n\n11/26/24 \n\n[Download PDF](/node/11381/pdf)\n\nLONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals International, plc](https://www.globenewswire.com/Tracker?data=Vd8zUnsNMkeu2QmwMqcTjgU2YknkQatS-pqNcIsf1gmfdTykdg25-aSgwPPpMQ3Z8Hr70LQwTCivX5UR10ERHuHIMs3ah2CPr6vkEkCIGWyJV6ZsFPGxpvWZ9U7wPgw5kREcTUFKhz9Z4ZxLJ5Rwvql1T8a27wwufXkQWHESq2Dvua8_ynRxJ72PLV6J7-iXLjT3ANMxdZRFpOSsYj0dqPZWmtA9hsglvz9hEmk7b1YpSdoInkOF4c7ML5lUu4HjOrMg2Zf6biCUHnXRC1iBcth7jPFySbwmAePxKLeuOFFFloCgrJ0tHITVJitcEMTm) (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.\n\nA live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at [www.kiniksa.com.](https://www.globenewswire.com/Tracker?data=Mx17rw0gcd2wLx6tgoj9Ox2EZ_n8PelN31o3MlPGrxiEz-_S17C6h8iqbeGuD5vJ9KTE3YbNBtChdjZyQ2DIkt6ArpqeKONY_94FCwpKuhkjydtaqSZnhVsowEoNAwCs) A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.\n\n**About Kiniksa** Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit [www.kiniksa.com](https://www.globenewswire.com/Tracker?data=Mx17rw0gcd2wLx6tgoj9O_aOv8-ttxBieLFXl4h1gftuwYyzc4GVB_RZBgUhRGNEC3x9x4Zj1pLNdEtIAkusezUUtQwLxMSYPBLn0LZvaDrB8c3ay2uW7QLmzYZd9RTqHmSkligzCskaYo3qDlM-eK9u8SS9ly_yY4x0qpzCvYTMSOoG8fwZTojXDGbTzvWsT3MJ-poOOhM6BVNGrqoy8O1L6pi35zoaykzk7D6Iv9Q=).\n\n**_Every Second Counts!_** **_®_**\n\n**Kiniksa Investor Contact** Jonathan Kirshenbaum (781) 829-3949[jkirshenbaum@kiniksa.com](https://www.globenewswire.com/Tracker?data=ytXCr9tvNmRf5-F8Id8LDrD58IXHNVzArT0oYGndme47UdwCChQTosmORRhcBwNOHkWj1E2EhmShfaOhu3J6bNmIhndvCLkBS0OJm3OigeY=)\n\n**Kiniksa Media Contact** Tyler Gagnon(781) 431-9100[tgagnon@kiniksa.com](https://www.globenewswire.com/Tracker?data=ICghUEOUTk8Jdz_BF3QLgB0YK6OHw_q8SGIryhUbi1uLhllYKn0Ui833Lqa4zeW8LNmD7NefwMSxtMij8ScRmSsfdxpNi7XDyKDXAvQVhag=)\n\n![](https://ml.globenewswire.com/media/NmI3YWQ2YjktYjMyYi00MTU2LTgyZGYtYmUzNTVmNjAzYjkxLTExMDkzNTc=/tiny/Kiniksa-Pharmaceuticals-Ltd-.png)\n\n[Print Page]()\n\n[RSS](/rss)\n\n[Email Alerts](/investor-resources/email-alerts)\n\n[Search](/search)\n"
        },
        {
          "title": "Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference",
          "url": "https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-pharmaceuticals-present-jefferies-london-healthcare",
          "content": "[ Skip to main navigation ](#main-menu)\n\nClose\n\n## Here for you, _every second_\n\nArea of Interest*Medical InformationBusiness DevelopmentHuman ResourcesInvestor & MediaPatient AdvocacyData Privacy\n\nSubmit\n\n*Required\n\n## Locations\n\n  * **United Kingdom** Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ\n  * **USA Headquarters** Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100\n  * **Switzerland** Kiniksa Pharmaceuticals, GmbH Grafenaustrasse 5 6302 Zug, Switzerland\n  * **USA California** Kiniksa Pharmaceuticals Corp. 4660 La Jolla Village Drive Suite 1025 San Diego, CA 92122\n\n\n\n[ ![Home](/sites/g/files/knoqqb90321/themes/site/nir_pid2524/dist/themes/custom/kiniksa/logo.png) ](https://www.kiniksa.com/)\n\nMenu\n\n#  Press Release Details \n\n## \n\nKiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference\n\n11/12/24 \n\n[Download PDF](/node/11336/pdf)\n\nLONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals International, plc](https://www.globenewswire.com/Tracker?data=ymgcCaHtQppuDjTbRDdoXo619uo4lmB7HxIe1jMUELZP__LTG3nO-bLM_brMs3wX_mGW-4vVMUjS4IHn4ODbgr1FbrTtHnuHL7BsacKh2wmORo915Tt5Ds6IUIJDQJlFjpgdBRLR-N1hI3gg84XT3ym3m0zfEZeQrF8FW13EySD1XeNfLM7yKXgp4_pEIo5SZ9viG2_UBoNefrDwxkpC0af7OAchmaYR4dqtdAv28T_vONV2XvptuQ8Sk4YNQmyDBtCMIojFoAUuerb11p1qqtVBZiGOc5Cdv8iyny_vdSCJCTFj_HJfJhArooDksQyQ) (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time).\n\nA live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at [www.kiniksa.com.](https://www.globenewswire.com/Tracker?data=LkL0XzCUgOCt_8OY8Sli2WbHJ_Fa-b-UC7ENDbYmD4tvhQO1joqldbPFcyP7YNJpGqOhxwrx-1biVUREARDMywivBNnLBlKez5QKUiEYxSI4RwWUtP7ZqSnir4fB2zXZ) A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.\n\n**About Kiniksa** Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit [www.kiniksa.com](https://www.globenewswire.com/Tracker?data=LkL0XzCUgOCt_8OY8Sli2TWKNInZ-p0pPtxHNdwTPIsdGex1fJKb3N2yb65dmR-3i5wK_FEooMMfTQaz7QukA61qg3jMymuJqlvxN_OZfJKzLmALOA-wUlBg0I_3jSuxkxq14ANOXCSmKRMz39CPzitOHWPZMlwMlW2SUhR9OzJVCkcR3aNvyFQ02uwRAonXnUxIubbQvRIKCxQ5Q9IhFU4WeGJuM2NbuFJGw6BtUzM=).\n\n**_Every Second Counts!_** **_®_**\n\n**Kiniksa Investor Contact** Jonathan Kirshenbaum (781) 829-3949[jkirshenbaum@kiniksa.com](https://www.globenewswire.com/Tracker?data=-gwd7fN2nqcFWhRT_37-8alb-VKRYZEbKayLeP08FuUMOhv4WIv6g0wAp9Vj3f7pzxbd-5kPer2H8vtzbQXLIMJut5IoOsLDyKBtV03dHts=)\n\n**Kiniksa Media Contact** Tyler Gagnon(781) 431-9100[tgagnon@kiniksa.com](https://www.globenewswire.com/Tracker?data=_I4vzKxxLpaO5SspGxtaw8aAIur-rtV7LLsI2OYcDjp_SSKtXC96HrV3nuepjI57OeAQpSbk4uAYNIakrLhkR2vafepYtWgfqDs4qhHm8xw=)\n\n![](https://ml.globenewswire.com/media/YWQ3MDYzM2UtY2Y1NS00YjNhLTgzM2YtMTZkMTYwMGM1ZjAyLTExMDkzNTc=/tiny/Kiniksa-Pharmaceuticals-Ltd-.png)\n\n[Print Page]()\n\n[RSS](/rss)\n\n[Email Alerts](/investor-resources/email-alerts)\n\n[Search](/search)\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "7th Annual Evercore ISI HealthCONx Conference",
          "url": "https://investors.kiniksa.com/events/event-details/7th-annual-evercore-isi-healthconx-conference",
          "content": "[ Skip to main navigation ](#main-menu)\n\nClose\n\n## Here for you, _every second_\n\nArea of Interest*Medical InformationBusiness DevelopmentHuman ResourcesInvestor & MediaPatient AdvocacyData Privacy\n\nSubmit\n\n*Required\n\n## Locations\n\n  * **United Kingdom** Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ\n  * **USA Headquarters** Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100\n  * **Switzerland** Kiniksa Pharmaceuticals, GmbH Grafenaustrasse 5 6302 Zug, Switzerland\n  * **USA California** Kiniksa Pharmaceuticals Corp. 4660 La Jolla Village Drive Suite 1025 San Diego, CA 92122\n\n\n\n[ ![Home](/sites/g/files/knoqqb90321/themes/site/nir_pid2524/dist/themes/custom/kiniksa/logo.png) ](https://www.kiniksa.com/)\n\nMenu\n\n#  Event Details \n\n## 7th Annual Evercore ISI HealthCONx Conference\n\n###  12/03/24 at 9:35 AM EST \n\n[Add to Outlook](/node/11371/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Kiniksa Pharmaceuticals - 7th Annual Evercore ISI HealthCONx Conference&dates=20241203T143500Z/20241203T143500Z&details=Event Details: http://investors.kiniksa.com/events/event-details/7th-annual-evercore-isi-healthconx-conference%0A%0AWebcast: https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=knsa&url=https://wsw.com/webcast/evercore44/knsa/2362311&location=&trp=false&sprop=&sprop=name:)\n\n[Listen to webcast](https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=knsa&url=https%3A//wsw.com/webcast/evercore44/knsa/2362311)\n\n[Print Page]()\n\n[RSS](/rss)\n\n[Email Alerts](/investor-resources/email-alerts)\n\n[Search](/search)\n"
        },
        {
          "title": "Jefferies London Healthcare Conference",
          "url": "https://investors.kiniksa.com/events/event-details/jefferies-london-healthcare-conference",
          "content": "[ Skip to main navigation ](#main-menu)\n\nClose\n\n## Here for you, _every second_\n\nArea of Interest*Medical InformationBusiness DevelopmentHuman ResourcesInvestor & MediaPatient AdvocacyData Privacy\n\nSubmit\n\n*Required\n\n## Locations\n\n  * **United Kingdom** Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ\n  * **USA Headquarters** Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100\n  * **Switzerland** Kiniksa Pharmaceuticals, GmbH Grafenaustrasse 5 6302 Zug, Switzerland\n  * **USA California** Kiniksa Pharmaceuticals Corp. 4660 La Jolla Village Drive Suite 1025 San Diego, CA 92122\n\n\n\n[ ![Home](/sites/g/files/knoqqb90321/themes/site/nir_pid2524/dist/themes/custom/kiniksa/logo.png) ](https://www.kiniksa.com/)\n\nMenu\n\n#  Event Details \n\n## Jefferies London Healthcare Conference\n\n### 11/19/24 at 7:00 AM EST / 12:00 PM GMT\n\n[Listen to webcast](https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=knsa&url=https%3A//wsw.com/webcast/jeff315/knsa/1846404)\n\n[Print Page]()\n\n[RSS](/rss)\n\n[Email Alerts](/investor-resources/email-alerts)\n\n[Search](/search)\n"
        }
      ]
    },
    {
      "section_name": "Financial Information",
      "links": [
        {
          "title": "Annual Reports & Proxy Statement",
          "url": "https://investors.kiniksa.com/financial-information/annual-reports",
          "content": null
        }
      ]
    }
  ]
}